Neuroendocrine causes of amenorrhea - An update

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages 812-824

  Fourman, Lindsay T ^a   Fazeli, Pouneh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOMIPRAMINE; CONTRACEPTIVE AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOMPERIDONE; FIBROBLAST GROWTH FACTOR 21; FLUOXETINE; INSULIN; LEPTIN; LEUPRORELIN; METHYLDOPA; METOCLOPRAMIDE; OPIATE; VERAPAMIL;

ACROMEGALY; ADRENAL TUMOR; BRAIN RADIATION; BRAIN SURGERY; CHRONIC KIDNEY FAILURE; CONGENITAL ADRENAL HYPERPLASIA; CUSHING DISEASE; DISORDERS OF HORMONE METABOLISM; DRUG INDUCED DISEASE; FUNCTIONAL HYPOTHALAMIC AMENORRHEA; GENE MUTATION; HEMOCHROMATOSIS; HUMAN; HYPERPROLACTINEMIA; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHALAMIC AMENORRHEA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; INFLAMMATORY INFILTRATE; LACTATION; LANGERHANS CELL HISTIOCYTOSIS; MACROPROLACTINEMIA; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PITUITARY STALK; PITUITARY SURGERY; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN FUNCTION; REVIEW; SARCOIDOSIS; SECONDARY AMENORRHEA; SELLA TURCICA TUMOR; THORAX INJURY; THYROTROPIN SECRETING ADENOMA; TRAUMATIC BRAIN INJURY; TUBERCULOSIS; ADENOMA; AMENORRHEA; COMPLICATION; FEMALE; HYPOPHYSIS ADRENAL SYSTEM; HYPOPHYSIS TUMOR; HYPOTHALAMUS DISEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NEUROSECRETION;

ADENOMA; AMENORRHEA; FEMALE; HUMANS; HYPERPROLACTINEMIA; HYPOTHALAMIC DISEASES; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; HYPOTHYROIDISM; KIDNEY FAILURE, CHRONIC; NEUROSECRETORY SYSTEMS; PITUITARY NEOPLASMS; PITUITARY-ADRENAL SYSTEM;

EID: 84924933194     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3344     Document Type: Review

References (129)

1. Reindollar RH, Novak M, Tho SP, McDonough PG. Adult-onset amenorrhea: a study of 262 patients. Am J Obstet Gynecol. 1986;155:531-543.
2. Barbarino A, De Marinis L, Tofani A, et al. Corticotropin-releasing hormone inhibition of gonadotropin release and the effect of opioid blockade. J Clin Endocrinol Metab. 1989;68:523-528.
3. Christian JJ. Actions of ACTH in intact and corticoid-maintained adrenalectomized female mice with emphasis on the reproductive tract. Endocrinology. 1964;75:653-669.
4. Biller BM, Federoff HJ, Koenig JI, Klibanski A. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 1990;70:311-317.
5. Dubey AK, Plant TM. A suppression of gonadotropin secretion by cortisol in castrated male rhesus monkeys (Macaca mulatta) mediated by the interruption of hypothalamic gonadotropin-releasing hormone release. Biol Reprod. 1985;33:423-431.
6. Boccuzzi G, Angeli A, Bisbocci D, Fonzo D, Giadano GP, Ceresa F. Effect of synthetic luteinizing hormone releasing hormone (LH-RH) on the release of gonadotropins in Cushing's disease. J Clin Endocrinol Metab. 1975;40:892-895.
7. Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab. 1975;40:774-779.
8. Rabin DS, Johnson EO, Brandon DD, Liapi C, Chrousos GP. Glucocorticoids inhibit estradiol-mediated uterine growth: possible role of the uterine estradiol receptor. Biol Reprod. 1990;42:74-80.
9. Miller KK, Parulekar MS, Schoenfeld E, et al. Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake. J Clin Endocrinol Metab. 1998;83:2309-2312.
10. Warren MP, Voussoughian F, Geer EB, Hyle EP, Adberg CL, Ramos RH. Functional hypothalamic amenorrhea: hypoleptinemia and disordered eating. J Clin Endocrinol Metab. 1999;84:873-877.
11. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351:987-997.
12. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA. 2011;108:6585-6590.
13. Quennell JH, Howell CS, Roa J, Augustine RA, Grattan DR, Anderson GM. Leptin deficiency and diet-induced obesity reduce hypothalamic kisspeptin expression in mice. Endocrinology. 2011;152:1541-1550.
14. Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289:2122-2125.
15. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-425.
16. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5:426-437.
17. Owen BM, Bookout AL, Ding X, et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med. 2013;19:1153-1156.
18. Matsuzaki T, Azuma K, Irahara M, Yasui T, Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil Steril. 1994;62:1143-1149.
19. Kooy A, de Greef WJ, Vreeburg JT, et al. Evidence for the involvement of corticotropin-releasing factor in the inhibition of gonadotropin release induced by hyperprolactinemia. Neuroendocrinology. 1990;51:261-266.
20. Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152:526-535.
21. Sonigo C, Bouilly J, Carré N, et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 2012;122:3791-3795.
22. Dorrington J, Gore-Langton RE. Prolactin inhibits oestrogen synthesis in the ovary. Nature. 1981;290:600-602.
23. Corenblum B, Pairaudeau N, Shewchuk AB. Prolactin hypersecretion and short luteal phase defects. Obstet Gynecol. 1976;47:486-488.
24. Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol. 1972;113:14-20.
25. Bonnar J, Franklin M, Nott PN, McNeilly AS. Effect of breastfeeding on pituitary-ovarian function after childbirth. Br Med J. 1975;4:82-84.
26. Valeggia C, Ellison PT. Interactions between metabolic and reproductive functions in the resumption of postpartum fecundity. Am J Hum Biol. 2009;21:559-566.
27. Díaz S, Serón-Ferré M, Cárdenas H, Schiappacasse V, Brandeis A, Croxatto HB. Circadian variation of basal plasma prolactin, prolactin response to suckling, and length of amenorrhea in nursing women. J Clin Endocrinol Metab. 1989;68:946-955.
28. Díaz S, Cárdenas H, Brandeis A, et al. Early difference in the endocrine profile of long and short lactational amenorrhea. J Clin Endocrinol Metab. 1991;72:196-201.
29. Campino C, Ampuero S, Díaz S, Serón-Ferré M. Prolactin bioactivity and the duration of lactational amenorrhea. J Clin Endocrinol Metab. 1994;79:970-974.
30. Zinaman MJ, Cartledge T, Tomai T, Tippett P, Merriam GR. Pulsatile GnRH stimulates normal cyclic ovarian function in amenorrheic lactating postpartum women. J Clin Endocrinol Metab. 1995;80:2088-2093.
31. Baird DT, McNeilly AS, Sawers RS, Sharpe RM. Failure of estrogen-induced discharge of luteinizing hormone in lactating women. J Clin Endocrinol Metab. 1979;49:500-506.
32. Hattori N, Ishihara T, Ikekubo K, Moridera K, Hino M, Kurahachi H. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992;75:1226-1229.
33. Hattori N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab. 1996;81:586-590.
34. Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab. 1997;82:3107-3110.
35. Jackson RD, Wortsman J, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab. 1985;61:258-264.
36. Leslie H, Courtney CH, Bell PM, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab. 2001;86:2743-2746.
37. Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002;87:581-588.
38. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999;51:119-126.
39. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102-2107.
40. Jacobs LS, Snyder PJ, Wilber JF, Utiger RD, Daughaday WH. Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab. 1971;33:996-998.
41. Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH. Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest. 1973;52:2324-2329.
42. Onishi T, Miyai K, Aono T, Shioji T, Yamamoto T. Primary hypothyroidism and galactorrhea. Am J Med. 1977;63:373-378.
43. Jawadi MH, Ballonoff LB, Stears JC, Katz FH. Primary hypothyroidism and pituitary enlargement. Radiological evidence of pituitary regression. Arch Intern Med. 1978;138:1555-1557.
44. Shahshahani MN, Wong ET. Primary hypothyroidism, amenorrhea, and galactorrhea. Arch Intern Med. 1978;138:1411-1412.
45. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50:846-852.
46. Morgan MY, Jakobovits AW, Gore MB, Wills MR, Sherlock S. Serum prolactin in liver disease and its relationship to gynaecomastia. Gut. 1978;19:170-174.
47. Ress C, Maeser PA, Tschoner A, et al. Serum prolactin in advanced chronic liver disease. Horm Metab Res. 2014;46:800-803.
48. Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab. 1977;45:931-935.
49. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab. 1998;83:3083-3088.
50. Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab. 1999;84:2731-2735.
51. Serafini P, Silva PD, Paulson RJ, Elkind-Hirsch K, Hernandez M, Lobo RA. Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women. Am J Obstet Gynecol. 1986;155:1288-1292.
52. Colao A, De Rosa M, Pivonello R, et al. Short-term suppression of GHand IGF-I levels improves gonadal function and sperm parameters in men with acromegaly. J Clin Endocrinol Metab. 2002;87:4193-4197.
53. Tritos NA, Eppakayala S, Swearingen B, et al. Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary. 2013;16:287-293.
54. Akande EO, Anderson DC. Role of sex-hormone-binding globulin in hormonal changes and amenorrhoea in thyrotoxic women. Br J Obstet Gynaecol. 1975;82:557-561.
55. Akande EO, Hockaday TD. Plasma concentration of gonadotrophins, oestrogens and progesterone in thyrotoxic women. Br J Obstet Gynaecol. 1975;82:541-551.
56. Komninos J, Vlassopoulou V, Protopapa D, et al. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab. 2004;89:574-580.
57. Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab. 1995;80:2302-2311.
58. Hunn BH, Martin WG, Simpson S Jr, Mclean CA. Idiopathic granulomatous hypophysitis: a systematic review of 82 cases in the literature. Pituitary. 2014;17:357-365.
59. Leporati P, Landek-Salgado MA, Lupi I, Chiovato L, Caturegli P. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab. 2011;96:1971-1980.
60. Stuart CA, Neelon FA, Lebovitz HE. Hypothalamic insufficiency: the cause of hypopituitarism in sarcoidosis. Ann Intern Med. 1978;88:589-594.
61. Ranjan A, Chandy MJ. Intrasellar tuberculoma. Br J Neurosurg. 1994;8:179-185.
62. Summers VK, Hipkin LJ, Osborne Hughes R, Davis JC. Panhypopituitarism after cured tuberculous meningitis. Br Med J. 1968;1:359.
63. Lam KS, Sham MM, Tam SC, Ng MM, Ma HT. Hypopituitarism after tuberculous meningitis in childhood. Ann Intern Med. 1993;118:701-706.
64. Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med. 1984;101:629-632.
65. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with Langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. 2000;85:1370-1376.
66. Goluboff LG, Ezrin C. Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab. 1969;29:1533-1538.
67. Zargar AH, Singh B, Laway BA, Masoodi SR, Wani AI, Bashir MI. Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan's syndrome). Fertil Steril. 2005;84:523-528.
68. Goswami R, Kochupillai N, Crock PA, Jaleel A, Gupta N. Pituitary autoimmunity in patients with Sheehan's syndrome. J Clin Endocrinol Metab. 2002;87:4137-4141.
69. Kristjansdottir HL, Bodvarsdottir SP, Sigurjonsdottir HA. Sheehan's syndrome in modern times: a nationwide retrospective study in Iceland. Eur J Endocrinol. 2011;164:349-354.
70. Ramiandrasoa C, Castinetti F, Raingeard I, et al. Delayed diagnosis of Sheehan's syndrome in a developed country: a retrospective cohort study. Eur J Endocrinol. 2013;169:431-438.
71. Benvenga S, Campenní A, Ruggeri RM, Trimarchi F. Clinical review 113: hypopituitarism secondary to head trauma. J Clin Endocrinol Metab. 2000;85:1353-1361.
72. Aimaretti G, Ambrosio MR, Di Somma C, et al. Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab. 2005;90:6085-6092.
73. Cordera F, Grant C, van Heerden J, Thompson G, Young W. Androgen-secreting adrenal tumors. Surgery. 2003;134:874-880.
74. Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature. 1991;353:529-536.
75. Dodé C, Levilliers J, Dupont JM, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet. 2003;33:463-465.
76. Falardeau J, Chung WC, Beenken A, et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest. 2008;118:2822-2831.
77. Young J, Metay C, Bouligand J, et al. SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Hum Reprod. 2012;27:1460-1465.
78. Bergman JE, de Ronde W, Jongmans MC, et al. The results of CHD7 analysis in clinically well-characterized patients with Kallmann syndrome. J Clin Endocrinol Metab. 2012;97:E858-E862.
79. Dodé C, Teixeira L, Levilliers J, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet. 2006;2:e175.
80. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18:213-215.
81. Clément K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature. 1998;392:398-401.
82. Jackson RS, Creemers JW, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997;16:303-306.
83. de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med. 1997;337:1597-1602.
84. Seminara SB, Beranova M, Oliveira LM, Martin KA, Crowley WF Jr, Hall JE. Successful use of pulsatile gonadotropin-releasing hormone (GnRH) for ovulation induction and pregnancy in a patient with GnRH receptor mutations. J Clin Endocrinol Metab. 2000;85:556-562.
85. Caronia LM, Martin C, Welt CK, et al. A genetic basis for functional hypothalamic amenorrhea. N Engl J Med. 2011;364:215-225.
86. Thomas PQ, Dattani MT, Brickman JM, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet. 2001;10:39-45.
87. Franc¸a MM, Jorge AA, Carvalho LR, et al. Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly. J Clin Endocrinol Metab. 2010;95:E384-E391.
88. Alatzoglou KS, Kelberman D, Cowell CT, et al. Increased transactivation associated with SOX3 polyalanine tract deletion in a patient with hypopituitarism. J Clin Endocrinol Metab. 2011;96:E685-E690.
89. Sato N, Kamachi Y, Kondoh H, et al. Hypogonadotropic hypogonadism in an adult female with a heterozygous hypomorphic mutation of SOX2. Eur J Endocrinol. 2007;156:167-171.
90. Netchine I, Sobrier ML, Krude H, et al. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet. 2000;25:182-186.
91. Pfaeffle RW, Hunter CS, Savage JJ, et al. Three novel missense mutations within the LHX4 gene are associated with variable pituitary hormone deficiencies. J Clin Endocrinol Metab. 2008;93:1062-1071.
92. Wu W, Cogan JD, Pfäffle RW, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet. 1998;18:147-149.
93. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 β-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab. 1983;56:222-229.
94. Rosenfield RL, Rich BH, Wolfsdorf JI, et al. Pubertal presentation of congenital δ 5-3 β-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1980;51:345-353.
95. New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91:4205-4214.
96. Bachelot A, Chakhtoura Z, Plu-Bureau G, et al. Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia. Eur J Endocrinol. 2012;167:499-505.
97. Melrose P, Gross L. Steroid effects on the secretory modalities of gonadotropin-releasing hormone release. Endocrinology. 1987;121:190-199.
98. Levin JH, Carmina E, Lobo RA. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil Steril. 1991;56:635-640.
99. Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab. 1999;84:4191-4196.
100. Zerah M, Ueshiba H, Wood E, et al. Prevalence of nonclassical steroid 21-hydroxylase deficiency based on a morning salivary 17-hydroxyprogesterone screening test: a small sample study. J Clin Endocrinol Metab. 1990;70:1662-1667.
101. Speiser PW, Dupont B, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet. 1985;37:650-667.
102. Chetkowski RJ, DeFazio J, Shamonki I, Judd HL, Chang RJ. The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women. J Clin Endocrinol Metab. 1984;58:595-598.
103. Kuttenn F, Couillin P, Girard F, et al. Late-onset adrenal hyperplasia in hirsutism. N Engl J Med. 1985;313:224-231.
104. Pang SY, Lerner AJ, Stoner E, et al. Late-onset adrenal steroid 3 β-hydroxysteroid dehydrogenase deficiency. I. A cause of hirsutism in pubertal and postpubertal women. J Clin Endocrinol Metab. 1985;60:428-439.
105. Baskin HJ. Screening for late-onset congenital adrenal hyperplasia in hirsutism or amenorrhea. Arch Intern Med. 1987;147:847-848.
106. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453-462.
107. Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab. 2008;93:527-533.
108. New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab. 1983;57:320-326.
109. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215-2222.
110. Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009;117:38-43.
111. Rasmussen DD, Liu JH, Wolf PL, Yen SS. Endogenous opioid regulation of gonadotropin-releasing hormone release from the human fetal hypothalamus in vitro. J Clin Endocrinol Metab. 1983;57:881-884.
112. Stubbs WA, Delitala G, Jones A, et al. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet. 1978;2:1225-1227.
113. Tolis G, Dent R, Guyda H. Opiates, prolactin, and the dopamine receptor. J Clin Endocrinol Metab. 1978;47:200-203.
114. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238-246.
115. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22:1085-1096.
116. Papakostas GI, Miller KK, Petersen T, et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006;67:952-957.
117. Golden RN, Hsiao J, Lane E, Hicks R, Rogers S, Potter WZ. The effects of intravenous clomipramine on neurohormones in normal subjects. J Clin Endocrinol Metab. 1989;68:632-637.
118. McCallum RW, Sowers JR, Hershman JM, Sturdevant RA. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab. 1976;42:1148-1152.
119. Sowers JR, Sharp B, McCallum RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab. 1982;54:869-871.
120. Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A. Effects of methyldopa on prolactin and growth hormone. Br Med J. 1976;1:1186-1188.
121. Kelley SR, Kamal TJ, Molitch ME. Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol. 1996;270:E96-E100.
122. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
123. Fatemi N, Dusick JR, Mattozo C, et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 2008;63:709-718; discussion 718-719.
124. Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88:4709-4719.
125. Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. 1986;81:457-462.
126. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med. 1993;328:87-94.
127. Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab. 2005;90:6355-6360.
128. Freda PU, Wardlaw SL, Post KD. Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab. 1996;81:3455-3459.
129. Valassi E, Biller BM, Klibanski A, Swearingen B. Clinical features of nonpituitary sellar lesions in a large surgical series. Clin Endocrinol (Oxf). 2010;73:798-807.